An Open-label Non-randomized, Phase 1 Study to Evaluate the Effect of (a) Itraconazole or Rifampin on the Pharmacokinetics of a Single Intravenous Dose of Copanlisib and (b) Copanlisib on Cardiovascular Safety in Subjects With Advanced Solid Tumors and Non-Hodgkin's Lymphoma
Latest Information Update: 05 Sep 2019
At a glance
- Drugs Copanlisib (Primary) ; Itraconazole; Rifampicin
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Bayer
- 30 Aug 2019 Status changed from active, no longer recruiting to completed.
- 16 Mar 2019 Results of physiologically-based pharmacokinetic modeling data presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 06 Jan 2019 Planned End Date changed from 19 Dec 2018 to 30 Sep 2019.